Notice: This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ERYP vs. PRME, SGMO, ENGN, VYGR, VALN, JSPR, FDMT, FATE, ITOS, and ATYRShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Prime Medicine (PRME), Sangamo Therapeutics (SGMO), enGene (ENGN), Voyager Therapeutics (VYGR), Valneva (VALN), Jasper Therapeutics (JSPR), 4D Molecular Therapeutics (FDMT), Fate Therapeutics (FATE), iTeos Therapeutics (ITOS), and Atyr PHARMA (ATYR). These companies are all part of the "biological products, except diagnostic" industry. ERYTECH Pharma vs. Prime Medicine Sangamo Therapeutics enGene Voyager Therapeutics Valneva Jasper Therapeutics 4D Molecular Therapeutics Fate Therapeutics iTeos Therapeutics Atyr PHARMA ERYTECH Pharma (NASDAQ:ERYP) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Is ERYP or PRME more profitable? ERYTECH Pharma's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets ERYTECH PharmaN/A N/A N/A Prime Medicine N/A -107.87%-74.97% Does the media refer more to ERYP or PRME? In the previous week, Prime Medicine had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Prime Medicine and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 equaled Prime Medicine'saverage media sentiment score. Company Overall Sentiment ERYTECH Pharma Neutral Prime Medicine Neutral Does the MarketBeat Community believe in ERYP or PRME? ERYTECH Pharma received 140 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 68.75% of users gave Prime Medicine an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote. CompanyUnderperformOutperformERYTECH PharmaOutperform Votes16257.45% Underperform Votes12042.55% Prime MedicineOutperform Votes2268.75% Underperform Votes1031.25% Do institutionals and insiders believe in ERYP or PRME? 1.1% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by company insiders. Comparatively, 23.5% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ERYP or PRME? ERYTECH Pharma has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Do analysts recommend ERYP or PRME? Prime Medicine has a consensus target price of $12.67, suggesting a potential upside of 336.78%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, ERYP or PRME? ERYTECH Pharma has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioERYTECH Pharma$32.66M3.24-$240KN/AN/APrime Medicine$800K475.46-$198.13M-$2.05-1.41 SummaryPrime Medicine beats ERYTECH Pharma on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.1317.19Price / Sales3.24415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / Book3.883.894.784.78Net Income-$240,000.00-$42.21M$120.31M$225.60M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049PRMEPrime Medicine2.9893 of 5 stars$3.21-1.8%$13.00+305.0%-66.9%$421.02MN/A0.00234SGMOSangamo Therapeutics1.7507 of 5 stars$2.01-0.2%$7.00+249.1%+537.4%$418.34M$52.29M-2.62480Analyst ForecastNews CoverageENGNenGene3.0079 of 5 stars$8.26-4.5%$30.38+267.7%-19.4%$365.26MN/A0.0031Earnings ReportNews CoveragePositive NewsGap UpVYGRVoyager Therapeutics4.6131 of 5 stars$6.44-0.2%$17.00+164.0%-29.4%$351.82M$250.01M9.08100VALNValneva2.1523 of 5 stars$4.31+4.1%$18.50+329.2%-60.1%$350.19M$165.52M0.00700News CoverageJSPRJasper Therapeutics2.3259 of 5 stars$22.57+0.4%$73.38+225.1%+287.7%$338.55MN/A0.0020News CoveragePositive NewsFDMT4D Molecular Therapeutics2.771 of 5 stars$7.21-1.9%$42.13+484.3%-69.1%$333.32M$20.72M-2.62201Analyst ForecastFATEFate Therapeutics3.5395 of 5 stars$2.75+3.8%$6.75+145.5%-49.9%$313.20M$63.53M0.00550ITOSiTeos Therapeutics3.5048 of 5 stars$8.38+0.7%$31.50+275.9%-28.8%$306.16M$35M-2.6690Analyst ForecastATYRAtyr PHARMA2.4718 of 5 stars$3.57+6.3%$19.25+439.2%N/A$299.67M$350,000.00-3.8756News CoverageHigh Trading Volume Related Companies and Tools Related Companies PRME Alternatives SGMO Alternatives ENGN Alternatives VYGR Alternatives VALN Alternatives JSPR Alternatives FDMT Alternatives FATE Alternatives ITOS Alternatives ATYR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERYP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
